Cargando...
P06.20 EGFRvIII: a predictive marker for Temozolomide response in O6-methylguanine-DNA methyltransferase negative glioblastoma cells and tumor xenografts
Glioblastoma multiforme (GBM) is the most common malignant brain tumor in adults with an estimated 5-year survival of less 10%. The current standard of care involves maximal tumor resection followed by radiation and chemotherapy with the alkylating agent temozolomide (TMZ). Epigenetic silencing of t...
Gardado en:
| Publicado en: | Neuro Oncol |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Oxford University Press
2016
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5782608/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/now188.111 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|